Compare ALEMBIC PHARMA with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PROCTER & GAMBLE HEALTH ALEMBIC PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 16.3 52.7 30.9% View Chart
P/BV x 3.7 4.8 78.6% View Chart
Dividend Yield % 1.0 10.0 10.2%  

Financials

 ALEMBIC PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
ALEMBIC PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs6643,549 18.7%   
Low Rs4121,301 31.7%   
Sales per share (Unadj.) Rs208.7511.4 40.8%  
Earnings per share (Unadj.) Rs31.061.3 50.6%  
Cash flow per share (Unadj.) Rs37.174.0 50.1%  
Dividends per share (Unadj.) Rs5.50440.00 1.3%  
Dividend yield (eoy) %1.018.1 5.6%  
Book value per share (Unadj.) Rs144.2927.8 15.5%  
Shares outstanding (eoy) m188.5216.60 1,135.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.7 54.4%   
Avg P/E ratio x17.439.6 43.9%  
P/CF ratio (eoy) x14.532.8 44.3%  
Price / Book Value ratio x3.72.6 142.8%  
Dividend payout %17.7717.9 2.5%   
Avg Mkt Cap Rs m101,46140,257 252.0%   
No. of employees `000NA1.1 0.0%   
Total wages/salary Rs m7,4671,313 568.8%   
Avg. sales/employee Rs ThNM7,486.7-  
Avg. wages/employee Rs ThNM1,157.6-  
Avg. net profit/employee Rs ThNM897.2-  
INCOME DATA
Net Sales Rs m39,3478,490 463.5%  
Other income Rs m94244 38.5%   
Total revenues Rs m39,4418,734 451.6%   
Gross profit Rs m8,7361,482 589.6%  
Depreciation Rs m1,152211 545.6%   
Interest Rs m1840-   
Profit before tax Rs m7,4931,514 494.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m1,568563 278.7%   
Profit after tax Rs m5,8441,017 574.4%  
Gross profit margin %22.217.5 127.2%  
Effective tax rate %20.937.1 56.3%   
Net profit margin %14.912.0 123.9%  
BALANCE SHEET DATA
Current assets Rs m19,57715,343 127.6%   
Current liabilities Rs m14,8961,960 759.9%   
Net working cap to sales %11.9157.6 7.5%  
Current ratio x1.37.8 16.8%  
Inventory Days Days9049 184.1%  
Debtors Days Days4528 159.4%  
Net fixed assets Rs m27,0971,209 2,240.7%   
Share capital Rs m377166 227.1%   
"Free" reserves Rs m26,81115,235 176.0%   
Net worth Rs m27,18815,401 176.5%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77817,595 271.5%  
Interest coverage x41.7NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.5 170.7%   
Return on assets %12.65.8 218.2%  
Return on equity %21.56.6 325.4%  
Return on capital %23.610.3 230.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,4531,636 1,188.8%   
Fx outflow Rs m6,0654,368 138.8%   
Net fx Rs m13,388-2,732 -490.1%   
CASH FLOW
From Operations Rs m8,120-1,304 -622.8%  
From Investments Rs m-7,55612,697 -59.5%  
From Financial Activity Rs m590-301 -196.5%  
Net Cashflow Rs m1,15311,093 10.4%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 2.9 18.2 15.9%  
FIIs % 9.1 1.0 910.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 29.1 47.8%  
Shareholders   49,328 28,591 172.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS